Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | CHIEF FINANCIAL OFFICER | January 07, 2026 | January 10, 2026 |
| Arcturus Therapeutics Holdings Inc.ARCT · Entity 5523 | Chief Financial Officer | May 01, 2026 | May 07, 2026 |
| LA JOLLA PHARMACEUTICAL COLJPC · Entity 124310 | Chief Financial Officer | May 29, 2020 | June 02, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date January 07, 2026 · Filed January 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,852 |
Ending reported balance
After 2026-01-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-01-07 · Exercise / conversion · Acquired 6,700 · Balance 24,367 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Row 2 · 2026-01-08 · Sale · Disposed 2,515 · Balance 21,852 F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 20,100 |
Reported balance
After 2026-01-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-07 · Exercise / conversion · Disposed 6,700 · Balance 20,100 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3: The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3: The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Arcturus Therapeutics Holdings Inc.
Report date May 01, 2026 · Filed May 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.63 · Expires 2036-05-01 | Direct | 100,000 |
Reported balance
After 2026-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-01 · Grant · Acquired 100,000 · Balance 100,000 F1: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. F2: The shares underlying this option vest 25% on May 1, 2027, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents options to purchase shares of common stock granted pursuant to the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.
F2: The shares underlying this option vest 25% on May 1, 2027, the first anniversary of the date of grant, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.
LA JOLLA PHARMACEUTICAL CO
Report date May 29, 2020 · Filed June 02, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,067 |
Reported balance
After 2020-05-29 transaction · row 1
1 source rowRow 1 · 2020-05-29 · Grant · Acquired 82 · Balance 5,067 F1: These shares were acquired on 05/29/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.72 · Expires 2030-05-29 | Direct | 82 |
Reported balance
After 2020-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-29 · Grant · Acquired 82 · Balance 82 F2: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired on 05/29/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 15, 2021 Filed Nov 17, 2021 22:16 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantCommon Stock | 964 | $22.03 | $21,236.92 |
DisclosureSEC source: 0001209191-21-065166 · doc4.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 964 F1 · shares: Represents shares of Common Stock acquired pursuant to the Issuer's Employee Stock Purchase Plan ("ESPP"), for the purchase period through November 15, 2021. In accordance with the ESPP, these shares were purchased at 85% of the lesser of the closing price of the Issuer's Common Stock on May 17, 2021 and November 15, 2021. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 02:27 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $29.70 | $0.00 |
DisclosureSEC source: 0001209191-21-010514 · doc4.xml · derivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2031-02-09 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 10, 2022, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 21:04 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantEmployee Stock Option (Right to Buy) · Derivative | 90,600 | $0.00 Strike: $20.16 | $0.00 |
DisclosureSEC source: 0001209191-20-042505 · doc4.xml · derivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,600 Underlying: Common Stock · 90,600 shares Expires 2030-07-12 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on July 15, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 16:03 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 82 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0000920465-20-000083 · wf-form4_159112816720839.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82 Underlying: Common Stock · 82 shares Expires 2030-05-29 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 16:03 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 82 | $4.01 | $328.82 |
DisclosureSEC source: 0000920465-20-000083 · wf-form4_159112816720839.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,067 F1 · kind: These shares were acquired on 05/29/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 15, 2020 Filed May 19, 2020 16:05 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 56 | $0.00 Strike: $6.89 | $0.00 |
DisclosureSEC source: 0000920465-20-000076 · wf-form4_158991874112950.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56 Underlying: Common Stock · 56 shares Expires 2030-05-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| May 15, 2020 Filed May 19, 2020 16:05 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 56 | $5.86 | $328.16 |
DisclosureSEC source: 0000920465-20-000076 · wf-form4_158991874112950.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,985 F1 · kind: These shares were acquired on 05/15/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 30, 2020 Filed May 4, 2020 16:08 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 53 | $0.00 Strike: $7.26 | $0.00 |
DisclosureSEC source: 0000920465-20-000063 · wf-form4_158862290582559.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53 Underlying: Common Stock · 53 shares Expires 2030-04-30 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| April 30, 2020 Filed May 4, 2020 16:08 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 53 | $6.17 | $327.01 |
DisclosureSEC source: 0000920465-20-000063 · wf-form4_158862290582559.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,929 F1 · kind: These shares were acquired on 04/30/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 16:03 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 58 | $0.00 Strike: $6.60 | $0.00 |
DisclosureSEC source: 0000920465-20-000051 · wf-form4_158715380065813.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58 Underlying: Common Stock · 58 shares Expires 2030-04-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 16:03 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 58 | $5.61 | $325.38 |
DisclosureSEC source: 0000920465-20-000051 · wf-form4_158715380065813.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,876 F1 · kind: These shares were acquired on 04/15/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 09, 2020 Filed Jan 13, 2020 16:17 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $5.25 | $0.00 |
DisclosureSEC source: 0000920465-20-000012 · wf-form4_157895022932210.xml · derivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-01-09 F1 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 16:34 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 16 | $0.00 Strike: $3.93 | $0.00 |
DisclosureSEC source: 0000920465-20-000003 · wf-form4_157808725121090.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16 Underlying: Common Stock · 16 shares Expires 2029-12-31 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 16:34 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 16 | $3.34 | $53.44 |
DisclosureSEC source: 0000920465-20-000003 · wf-form4_157808725121090.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,818 F1 · kind: These shares were acquired on 12/31/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 16:03 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 112 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0000920465-19-000174 · wf-form4_157661659450059.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112 Underlying: Common Stock · 112 shares Expires 2029-12-13 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 16:03 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 112 | $2.85 | $319.20 |
DisclosureSEC source: 0000920465-19-000174 · wf-form4_157661659450059.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,802 F1 · kind: These shares were acquired on 12/13/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 16:27 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 138 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0000920465-19-000168 · wf-form4_157540844730842.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138 Underlying: Common Stock · 138 shares Expires 2029-11-29 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 16:27 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 138 | $2.33 | $321.54 |
DisclosureSEC source: 0000920465-19-000168 · wf-form4_157540844730842.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,690 F1 · kind: These shares were acquired on 11/29/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 16:11 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 62 | $0.00 Strike: $6.02 | $0.00 |
DisclosureSEC source: 0000920465-19-000162 · wf-form4_157419790020747.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62 Underlying: Common Stock · 62 shares Expires 2029-11-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 16:11 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 62 | $5.12 | $317.44 |
DisclosureSEC source: 0000920465-19-000162 · wf-form4_157419790020747.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,552 F1 · kind: These shares were acquired on 11/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| October 31, 2019 Filed Nov 5, 2019 16:04 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 267 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0000920465-19-000150 · wf-form4_157298788254421.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267 Underlying: Common Stock · 267 shares Expires 2029-10-31 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| October 31, 2019 Filed Nov 5, 2019 16:04 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 267 | $5.96 | $1,591.32 |
DisclosureSEC source: 0000920465-19-000150 · wf-form4_157298788254421.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,490 F1 · kind: These shares were acquired on 10/31/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 17:41 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 224 | $0.00 Strike: $8.38 | $0.00 |
DisclosureSEC source: 0000920465-19-000143 · wf-form4_157134842257231.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224 Underlying: Common Stock · 224 shares Expires 2029-10-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 17:41 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 224 | $7.12 | $1,594.88 |
DisclosureSEC source: 0000920465-19-000143 · wf-form4_157134842257231.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,223 F1 · kind: These shares were acquired on 10/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 17:05 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 213 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0000920465-19-000136 · wf-form4_157005031693872.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213 Underlying: Common Stock · 213 shares Expires 2029-09-30 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 17:05 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 213 | $7.48 | $1,593.24 |
DisclosureSEC source: 0000920465-19-000136 · wf-form4_157005031693872.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,999 F1 · kind: These shares were acquired on 09/30/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| September 13, 2019 Filed Sep 16, 2019 19:24 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 171 | $0.00 Strike: $10.92 | $0.00 |
DisclosureSEC source: 0000920465-19-000128 · wf-form4_156867625577243.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171 Underlying: Common Stock · 171 shares Expires 2029-09-13 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| September 13, 2019 Filed Sep 16, 2019 19:24 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 171 | $9.28 | $1,586.88 |
DisclosureSEC source: 0000920465-19-000128 · wf-form4_156867625577243.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,786 F1 · kind: These shares were acquired on 09/13/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| August 30, 2019 Filed Sep 3, 2019 16:13 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 196 | $0.00 Strike: $9.57 | $0.00 |
DisclosureSEC source: 0000920465-19-000121 · wf-form4_156754156886073.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196 Underlying: Common Stock · 196 shares Expires 2029-08-30 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| August 30, 2019 Filed Sep 3, 2019 16:13 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 196 | $8.13 | $1,593.48 |
DisclosureSEC source: 0000920465-19-000121 · wf-form4_156754156886073.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,615 F1 · kind: These shares were acquired on 08/30/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 16:50 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 198 | $0.00 Strike: $9.43 | $0.00 |
DisclosureSEC source: 0000920465-19-000110 · wf-form4_156598862430306.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198 Underlying: Common Stock · 198 shares Expires 2029-08-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 16:50 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 198 | $8.02 | $1,587.96 |
DisclosureSEC source: 0000920465-19-000110 · wf-form4_156598862430306.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,419 F1 · kind: These shares were acquired on 08/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 16:59 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 224 | $0.00 Strike: $8.36 | $0.00 |
DisclosureSEC source: 0000920465-19-000105 · wf-form4_156477958390697.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224 Underlying: Common Stock · 224 shares Expires 2029-07-31 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 16:59 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 224 | $7.11 | $1,592.64 |
DisclosureSEC source: 0000920465-19-000105 · wf-form4_156477958390697.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,221 F1 · kind: These shares were acquired on 07/31/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 17:11 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 203 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0000920465-19-000098 · wf-form4_156339784958788.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203 Underlying: Common Stock · 203 shares Expires 2029-07-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 17:11 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 203 | $7.85 | $1,593.55 |
DisclosureSEC source: 0000920465-19-000098 · wf-form4_156339784958788.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,997 F1 · kind: These shares were acquired on 07/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 28, 2019 Filed Jul 1, 2019 18:12 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 202 | $0.00 Strike: $9.25 | $0.00 |
DisclosureSEC source: 0000920465-19-000094 · wf-form4_156201911135934.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202 Underlying: Common Stock · 202 shares Expires 2029-06-28 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| June 28, 2019 Filed Jul 1, 2019 18:12 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 202 | $7.86 | $1,587.72 |
DisclosureSEC source: 0000920465-19-000094 · wf-form4_156201911135934.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,794 F1 · kind: These shares were acquired on 06/28/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 14, 2019 Filed Jun 18, 2019 16:44 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 193 | $0.00 Strike: $9.71 | $0.00 |
DisclosureSEC source: 0000920465-19-000089 · wf-form4_156089067598117.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193 Underlying: Common Stock · 193 shares Expires 2029-06-14 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| June 14, 2019 Filed Jun 18, 2019 16:44 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 193 | $8.25 | $1,592.25 |
DisclosureSEC source: 0000920465-19-000089 · wf-form4_156089067598117.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,592 F1 · kind: These shares were acquired on 06/14/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 19:26 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 347 | $0.00 Strike: $5.39 | $0.00 |
DisclosureSEC source: 0000920465-19-000083 · wf-form4_155960436247457.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347 Underlying: Common Stock · 347 shares Expires 2029-05-31 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 19:26 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 347 | $4.58 | $1,589.26 |
DisclosureSEC source: 0000920465-19-000083 · wf-form4_155960436247457.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,399 F1 · kind: These shares were acquired on 05/31/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 15, 2019 Filed May 17, 2019 16:06 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 285 | $0.00 Strike: $6.57 | $0.00 |
DisclosureSEC source: 0000920465-19-000079 · wf-form4_155812355260353.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285 Underlying: Common Stock · 285 shares Expires 2029-05-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| May 15, 2019 Filed May 17, 2019 16:06 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 285 | $5.58 | $1,590.30 |
DisclosureSEC source: 0000920465-19-000079 · wf-form4_155812355260353.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,052 F1 · kind: These shares were acquired on 05/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 30, 2019 Filed May 2, 2019 17:12 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 233 | $0.00 Strike: $8.05 | $0.00 |
DisclosureSEC source: 0000920465-19-000071 · wf-form4_155683152923189.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233 Underlying: Common Stock · 233 shares Expires 2029-04-30 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| April 30, 2019 Filed May 2, 2019 17:12 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 233 | $6.84 | $1,593.72 |
DisclosureSEC source: 0000920465-19-000071 · wf-form4_155683152923189.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,767 F1 · kind: These shares were acquired on 04/30/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 17:02 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 261 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0000920465-19-000061 · wf-form4_155553493410654.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261 Underlying: Common Stock · 261 shares Expires 2029-04-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 17:02 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 261 | $6.09 | $1,589.49 |
DisclosureSEC source: 0000920465-19-000061 · wf-form4_155553493410654.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,534 F1 · kind: These shares were acquired on 04/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 19:07 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 59 | $0.00 Strike: $6.43 | $0.00 |
DisclosureSEC source: 0000920465-19-000058 · wf-form4_155424645767599.xml · derivative · entry 2 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59 Underlying: Common Stock · 59 shares Expires 2029-03-29 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 19:07 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 59 | $5.47 | $322.73 |
DisclosureSEC source: 0000920465-19-000058 · wf-form4_155424645767599.xml · nonDerivative · entry 1 MULROY DENNIS · CIK 0001276840 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,273 F1 · kind: These shares were acquired on 03/29/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.